Biological-162 is under clinical development by Yangshengtang and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Biological-162’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Antibody (162) is under development for the treatment of chronic hepatitis B virus (HBV) infection. The therapeutic candidate comprises of neutralizing antibody and acts by targeting Hepatitis B virus surface antigen.
Yangshengtang is a pharmaceutical company that includes the manufacturing, fabricating, and processing of drugs. The company is headquartered in Hangzhou, China.
For a complete picture of Biological-162’s drug-specific PTSR and LoA scores, buy the report here.